SYMBICORT for your asthma patients ≥12 years of age uncontrolled on an ICS or whose disease severity clearly warrants an ICS/LABA

The efficacy of SYMBICORT

In a 12-week efficacy and safety study of patients with moderate to severe asthma:

SYMBICORT 160/4.5 significantly improved predose FEV1 (P<.05 vs budesonide, formoterol, and placebo) averaged over the course of the study, and also improved 12-hour average postdose FEV1 (P<.001 vs budesonide, formoterol, and placebo at week 2), coprimary endpoints1; 2-hour postdose FEV1 over 12 weeks was a secondary endpoint.2

SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

 

SYMBICORT for your asthma patients ≥12 years of age uncontrolled on an ICS or whose disease severity clearly warrants an ICS/LABA

The efficacy of SYMBICORT

In a 12-week efficacy and safety study of patients with moderate to severe asthma:

SYMBICORT 160/4.5 significantly improved predose FEV1 (P<.05 vs budesonide, formoterol, and placebo) averaged over the course of the study, and also improved 12-hour average postdose FEV1 (P<.001 vs budesonide, formoterol, and placebo at week 2), coprimary endpoints1; 2-hour postdose FEV1 over 12 weeks was a secondary endpoint.2

SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

Click on the links below to view clinical data about the efficacy and safety of SYMBICORT in the treatment of asthma: